Treatment of Stage 4s Neuroblastoma: 10 Years of Experience
Author Information
Author(s): Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Mechinaud F, Michon J
Primary Institution: Institut Curie
Hypothesis
What are the clinical and biological prognostic factors in infants with stage 4s neuroblastoma treated by the French Society of Paediatric Oncology?
Conclusion
The study found that stage 4s neuroblastoma has a high overall survival rate of 88%, with many infants achieving good outcomes even with minimal treatment.
Supporting Evidence
- Stage 4s neuroblastoma represents approximately 7-10% of all neuroblastoma cases.
- Infants with stage 4s neuroblastoma have a high chance of spontaneous regression.
- The overall survival rate for infants with stage 4s neuroblastoma was found to be 88%.
- Patients who did not require medical intervention had a 100% survival rate.
- Elevated serum ferritin and NSE levels were associated with worse outcomes.
Takeaway
This study looked at babies with a type of cancer called neuroblastoma and found that most of them can get better even without much treatment.
Methodology
The study analyzed clinical data from 94 infants with stage 4s neuroblastoma treated between 1990 and 2000, focusing on treatment strategies and outcomes.
Potential Biases
Treatment decisions were not standardized and were subject to the subjective judgment of treating physicians.
Limitations
The study is retrospective and lacks a randomized control group, which may affect the generalizability of the findings.
Participant Demographics
The cohort included 50 boys and 44 girls, with a mean age at diagnosis of 66 days.
Statistical Information
P-Value
p<0.05
Confidence Interval
±7.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website